J Cancer 2016; 7(15):2296-2303. doi:10.7150/jca.16629
Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies
1. Laboratory of Genetics, Butantan Institute;
2. Department of Morphology and Genetics, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil.
*These authors contributed equally to this work.
Cancer cells transformation into a normal state or into a cancer cell population which is less tumorigenic than the initial one is a challenge that has been discussed during last decades and it is still far to be solved. Due to the highly heterogeneous nature of cancer cells, such transformation involves many genetic and epigenetic factors which are specific for each type of tumor. Different methods of cancer cells reprogramming have been established and can represent a possibility to obtain less tumorigenic or even normal cells. These methods are quite complex, thus a simple and efficient method of reprogramming is still required. As soon as induced pluripotent stem cells (iPSC) technology, which allowed to reprogram terminally differentiated cells into embryonic stem cells (ESC)-like, was developed, the method strongly attracted the attention of researches, opening new perspectives for stem cell (SC) personalized therapies and offering a powerful in vitro model for drug screening. This technology is also used to reprogram cancer cells, thus providing a modern platform to study cancer-related genes and the interaction between these genes and the cell environment before and after reprogramming, in order to elucidate the mechanisms of cancer initiation and progression. The present review summarizes recent advances on cancer cells reprogramming using iPSC technology and shows the progress achieved in such field.
Keywords: Reprogramming, Yamanaka`s factors, Cancer cells, Induced pluripotent stem cells.
Câmara DAD, Mambelli LI, Porcacchia AS, Kerkis I. Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies. J Cancer 2016; 7(15):2296-2303. doi:10.7150/jca.16629. Available from http://www.jcancer.org/v07p2296.htm